Recent Therapeutic Approaches for Migraine Management: The Latest Developments in Diagnosis and Prevention

A continuing medical education activity provided by NAMCP and AAMCN

This activity is an archive of the live session from the 2021 Spring Managed Care Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from July 1, 2021 – August 1, 2022
 

Instructions for CME/NCPD: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.

 

Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This activity is supported by an educational grant from
Teva Pharmaceuticals

Description:
Migraine is a major neurological disease that affects more than 36 million men, women and children in the United States. The disease impacts 1 in 4 households, 1 in 5 women, 1 in 16 men, and 1 in 11 children in the United States. Migraine headache is the most common type of headache presented by patients that seek medical treatment, and the World Health Organization (WHO) has ranked migraine in the top fifteen most disabling medical conditions. In many patients with migraine headache, their pain is unrelieved, and recurrence of migraine is a common reason for patient dissatisfaction with treatment. Although approximately 38% of migraineurs need preventive therapy, only 3% to 13% currently use it. The fact that diagnosis is based entirely on clinical history poses a challenge for healthcare professionals, as migraine is only 1 of approximately 300 headache disorders. Although accurate diagnosis is needed for appropriate treatment, currently available migraine therapy is often inadequate. Fortunately for patients who suffer from migraine headaches, a new class of therapy has emerged that offers vastly improved efficacy and safety over traditional treatment regimens. Calcitonin gene-related peptide (CGRP) monoclonal antibodies offer healthcare professionals a new and improved armamentarium in the treatment and prevention of migraines.

The diagnosis of a migraine is based on signs and symptoms. Neuroimaging tests are not necessary to diagnose migraine, but may be used to find other causes of headaches in those whose examination and history do not confirm a migraine diagnosis. It is believed that a substantial number of people with the condition remain undiagnosed, which stresses the importance of proper screening and diagnostic tools and strategies. Patients with frequent migraines and/or who experience functional disability need preventative migraine treatment. While traditional pharmaceutical intervention has worked adequately in the past, new and emerging options are available that have shown the ability to vastly improve outcomes, quality of life and adherence in migraine patients. CGRP monoclonal antibodies are specifically designed to bind to and inhibit the activity of CGRP that may prevent or significantly reduce the frequency of monthly migraine headache days in patients with episodic and chronic migraine and cluster headache. The role of CGRP in migraine has been verified by basic research. The peptide is present throughout the trigeminovascular system and in central brain regions. During spontaneous migraine attacks, jugular-venous blood concentrations of CGRP increase, and the recombinant human CGRP can induce a migraine attack. Monoclonal antibodies targeting CGRP have become available in the preventative management of migraine.

Upon completion of this activity, participants will be able to:

  • Analyze guideline-recommended treatment strategies to address unmet clinical and economic burdens for patients with migraine

  • Describe diagnostic and evidence-based strategies to differentiate migraine from other headache disorders

  • Examine the role of calcitonin gene-related peptide (CGRP) in the pathophysiology of migraine

  • Explore the efficacy, safety, and tolerability of CGRP monoclonal antibodies in the prevention and management of migraine

  • Discuss the managed care considerations of anti-CGRP therapies by exploring where these agents fit in the evolving migraine prevention paradigm

  • Assess comprehensive management plans for migraine patients based on preventative treatment and promoting adherence

     

Faculty: Andrew Charles, MD
Professor of Neurology
Director, UCLA Goldberg Migraine Program
Meyer and Renee Luskin Chair in Migraine and Headache Studies
David Geffen School of Medicine at UCLA
 

Disclosure:

Dr. Charles serves as a consultant for Amgen, Biohaven, Lilly, Lundbeck, Satsuma, and My Everyday Health. He serves on the speaker's bureau for Lundbeck. His presentation has been peer reviewed for any bias.
  Planning Committee:
Bill Williams, MD has no financial relationships with ineligible companies to disclose.
Jeremy Williams has no financial relationships with ineligible companies to disclose.
Jacqueline Cole, RN, MS, CMCN has no financial relationships with ineligible companies to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the National Association of Managed Care Physicians (NAMCP) and American Association of Managed Care Nurses (AAMCN). The National Association of Managed Care Physicians is accredited by the ACCME to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their participation in the activity.

The American Association of Managed Care Nurses is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in nursing continuing professional development.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This activity is supported by an educational grant from
Teva Pharmaceuticals

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue